Medexus Pharmaceuticals (TSE:MDP) Price Target Raised to C$6.00 at Stifel Nicolaus

Medexus Pharmaceuticals (TSE:MDP) had its price target lifted by equities research analysts at Stifel Nicolaus from C$4.50 to C$6.00 in a research report issued on Thursday,BayStreet.CA reports. Stifel Nicolaus’ price objective would indicate a potential upside of 51.13% from the company’s previous close.

Several other brokerages have also commented on MDP. Ventum Cap Mkts raised Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective on the stock in a research report on Wednesday, January 8th. Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Finally, Leede Financial upgraded shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, January 22nd. Two equities research analysts have rated the stock with a buy rating and five have given a strong buy rating to the company. According to data from MarketBeat, Medexus Pharmaceuticals presently has a consensus rating of “Strong Buy” and an average price target of C$6.13.

Medexus Pharmaceuticals Price Performance

Shares of TSE MDP traded down C$0.03 during mid-day trading on Thursday, reaching C$3.97. 122,000 shares of the company’s stock were exchanged, compared to its average volume of 192,164. Medexus Pharmaceuticals has a 52 week low of C$1.47 and a 52 week high of C$5.56. The firm has a 50-day moving average price of C$3.37 and a two-hundred day moving average price of C$2.76. The firm has a market capitalization of C$97.38 million, a price-to-earnings ratio of 79.40 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.